FFA
SGMT icon

Farther Finance Advisors’s Sagimet Biosciences SGMT Stock Holding History

Farther Finance Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39
Closed -$268 – 5578
2025
Q3 		$268 Buy
+39
New +$316 ﹤0.01% 4667

Other funds holding SGMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Farther Finance Advisors's SGMT Position: Q4 2025 in Review

Farther Finance Advisors sold out of Sagimet Biosciences (SGMT) in Q4 2025, closing a stake of 39 shares — an estimated $268 sold.

Farther Finance Advisors first reported a position in SGMT in Q3 2025 and held it in 1 quarter. The position peaked at $268 in Q3 2025. 86 funds tracked by Wall St. Rank hold SGMT as of Q4 2025.

  • Farther Finance Advisors reported no remaining Sagimet Biosciences position as of Q4 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 39 Sagimet Biosciences shares in Q4 2025, an estimated $268.
  • Farther Finance Advisors first reported a position in Sagimet Biosciences in Q3 2025 and held it in 1 quarter.
  • Farther Finance Advisors's Sagimet Biosciences position peaked at $268 in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2025.

Based on Farther Finance Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.